Alvotech - Ordinary Shares (ALVO)

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.

ALVO stock results show that Alvotech missed on revenue for the second quarter of 2024.

Alvotech just reported results for the fourth quarter of 2023.

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024.

It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.

Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.

FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion.